XL647
Phase 2- Indications
- Non-small cell lung cancer
Company intelligence / Profile preview
Symphony Evolution
Rockville, Maryland, United Statesdnb.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Symphony Evolution develops clinical-stage programs targeting cancer and diabetic nephropathy. The company was formed to collaborate with Exelixis on these therapeutic areas. Specific clinical results are not detailed in available sources.
- Therapeutic areas
- OncologyNephrology
- Modalities
- Small moleculeAntibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exelixis
Beyond the preview
Go deeper on Symphony Evolution.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Symphony Evolution.